Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ICH Q12 Experts Develop Four-Tier Scheme For Harmonizing Post-Approval Changes

Executive Summary

Ambitious effort to enable fuller, quicker rollout of post-approval manufacturing changes progressed at ICH meeting in Lisbon, participants told recent conferences. Much of the focus of ICH Q12 discussion was on harmonized reporting categories so manufacturers could make more changes before obtaining approval – and in some cases without even seeking approval.


Related Content

‘Critical’ Issues Need Resolution Before ICH Q12 Proceeds To Next Step
Quality Regulatory Updates In Brief: ICH, EMA, MHRA and FDA
FDA Encourages 'Established Conditions' Use Despite ICH Q12 Uncertainty
Why Industry Says Global Post-Approval Complexity Must Change
Why Industry Says Global Post-Approval Complexity Must Change
FDA Would Establish Conditions for Swift Manufacturing Changes
ICH Q12 to Foster Post-Approval Change Management
Biotechs Complain About International Post-Approval Change Complexity





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst